For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
At the center of deployment is mlHealth360’s proprietary Scaida AI platform, designed to detect and triage abnormalities in CT scans
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The new capital is expected to fund the company through 2029
Its a major breakthrough for women’s ovarian cancer care in Europe
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
Subscribe To Our Newsletter & Stay Updated
